C&L: Opexa CEO to retire

GeoVax Labs has added Dr. Robert McNally as president and CEO. 

Opexa Therapeutics announced that David McWilliams, president and CEO, will retire following the naming of his successor. 

Synthetic Blood International announced the death of interim CEO Robert Larsen. He was 79. Chris J. Stern, DBA, chairman of Synthetic Blood International's board of directors, will take over Larsen's roles. 

Icagen has promoted Richard Katz, M.D. to executive vice president, finance and corporate development, and chief financial officer.

Metabolix announced that Joseph Hill has been appointed chief financial officer. 

Biophage Pharma announced that Louis Guindon has resigned as chief financial officer. 

Acura Pharmaceuticals announced that Robert Jones has been named senior vice president and chief operating officer. 

Zelos Therapeutics has appointed David Krause, MD, FACP, as the company's senior vice president of R&D and chief medical officer. 

Cubist Pharmaceuticals has named Tamara Joseph as senior vice president. 

Monogram Biosciences has promoted Gordon Parry, PhD, to the position of vice president, research and development, oncology. 

Conatus Pharmaceuticals has named Anthony "Tony" Fox as part-time chief medical officer to oversee the recently initiated Phase 2 clinical trial of CTS-1027 in Hepatitis C virus-infected patients as well as assisting in the development of the longer-term clinical development plans. 

Codexis has named David Anton, Ph.D. to the newly-created position of vice president, bioindustrials research and development. 

Kinexum Metabolics has named Peter Damsbo, M.D. to the clinical development team that is designing human trials for INGAP Peptide which are scheduled to begin in 2008. 

Sernova Corp. has added Dr. Shinichi Matsumoto, director of the Baylor All Saints Islet Cell Laboratory at the Baylor Research Institute in Fort Worth Texas, to its Scientific Advisory Board. 

Micromet has named five leading oncology and immunology researchers to its newly formed panel of BiTE antibody advisors. They are: Richard Flavell (Yale University, New Haven, Connecticut); Michael Keating (MD Anderson Cancer Center, Houston, Texas); Ronald Levy (Stanford University, Stanford, California); Jeffrey Ravetch (Rockefeller University, New York, New York); and Anthony Tolcher (South Texas Accelerated Research Therapeutics, San Antonio, Texas). 

Avexa announced that its chairman, Dr. Hugh Niall, has retired from the board of the company. 

GlobeImmune has added J. William Freytag, Ph.D. to its board of directors. 

Sirtris Pharmaceuticals has named Paul Friedman, M.D., president and CEO of Incyte Corporation, to its board of directors. 

Hana Biosciences has named Paul Maier to its board of directors. 

H. Ward Wolff has been appointed to the board of Map Pharmaceuticals.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.